Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception
Trial details
- Registry ID
- NCT01218789
- Phase
- Phase 3
The FDA approved tasimelteon (VEC-162) on 31 Jan 2014.
Drug identity checked against registry records
Also recorded as VEC-162
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionNCT01218789 | Vanda Pharmaceuticals | Phase 3 | Unknown | 2024-12-05Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-01-31Day | tasimelteon | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA205677", "applicant_as_listed_by_fda": "VANDA PHARMS INC", "brand_names": ["HETLIOZ"], "active_ingredients": ["TASIMELTEON"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140131", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |